Background: The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate to ...

The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according ...

Oppenheimer analyst Matthew Biegler met with Fulcrum Therapeutics (FULC)’ management Tuesday after the company reported year-end financials.

Alex Sapir; President, Chief Executive Officer, Director; Fulcrum Therapeutics Inc. Alan Musso; Chief Financial Officer, Treasurer; Fulcrum Therapeutics Inc. Lain Fr ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Government think tank NITI Aayog has formed a committee to create a roadmap aimed at transforming AIIMS, New Delhi, into a ...

TANZANIA: SICKLE Cell Disease (SCD) remains a significant health burden, particularly in Africa where approximately 80 per ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

Objective This study aims to evaluate the markers of tubular phosphate handling in adults with sickle cell anemia (SCA) and the influence of hydroxyurea (HU), the degree of anemia and Hb F ...

NITI Aayog sets up a committee to revamp AIIMS, New Delhi, into a leading medical research and practice institution. The ...